Inebilizumab

Inebilizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	CD19
Clinical data
Pronunciation	/ɪˌnɛbɪˈlɪzjʊmæb/; ih-NEH-bih-LIZ-yuum-ab
Trade names	Uplizna
Other names	MEDI-551, inebilizumab-cdon
AHFS/Drugs.com	Monograph
License data	US DailyMed: Inebilizumab;
Routes of; administration	Intravenous
Drug class	Antineoplastic agent
ATC code	L04AG10 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1299440-37-1;
DrugBank	DB12530;
ChemSpider	None;
UNII	74T7185BMM;
KEGG	D11757;
Chemical and physical data
Formula	C6504H10080N1732O2044S44
Molar mass	146652.90 g·mol−1

Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults and IgG4-RD. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells.

The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain.

Inebilizumab was approved for medical use in the United States in June 2020, in the European Union in April 2022, and in Canada in December 2023. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.